USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: LYPRO BIOSCIENCES, INC.
City: Berkeley
State: CA
Zip+4: 94710
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $209,354.00 2
SBIR Phase II $2,299,281.00 2

Award List:

Inhalable amphotericin B nanodisk therapy for pulmonary aspergillosis

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trudy M. Forte
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Aspergillus fumigatus is an opportunistic pathogenic fungus that predominantly infects immunocompromised patients. It is the most common cause of infectious pneumonic mortality in HIV patients, organ transplant recipients, and cancer patients. Treatment is… More

NanoDisk-Amphotericin B therapy for aspergillosis

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Trudy M. Forte
Award Amount: $827,430.00
Abstract:
DESCRIPTION (provided by applicant): Aspergillus fumigatus is an opportunistic pathogenic fungus that predominantly infects immunocompromised patients. It is the most common cause of infectious pneumonic mortality in HIV patients, organ transplant recipie nts, and cancer patients. A. fumigatus… More

Nanobiotechnology for the Treatment of Mantle Cell Lymphoma

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Trudy M. Forte
Award Amount: $109,354.00
Abstract:
DESCRIPTION (provided by applicant): Mantle cell lymphoma (MCL) is a B-cell malignancy that is characterized by dysregulation of various oncogenes. Building on evidence that retinoic acid and its derivative, all trans retinoic acid (ATRA), are useful agent s that potentiate apoptosis or… More

NanoDisk-Amphotericin B therapy for aspergillosis

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Trudy M. Forte
Award Amount: $1,471,851.00
Abstract:
DESCRIPTION (provided by applicant): Aspergillus fumigatus is an opportunistic pathogenic fungus that predominantly infects immunocompromised patients. It is the most common cause of infectious pneumonic mortality in HIV patients, organ transplant recipients, and cancer patients. A. fumigatus… More